Revelation Biosciences, Inc. (REVB)

Revelation Biosciences, Inc. (REVB) stock has experienced significant volatility and a downward trend, declining by 68.42% in the past six months. Key events impacting the stock price include reverse stock splits, warrant exercises, financial results, regulatory and clinical progress, and stock offerings. The company announced a 1-for-3 reverse stock split on July 1, 2025, and a 1-for-16 reverse stock split on January 24, 2025, which became effective on January 28, 2025, to regain Nasdaq compliance. Revelation Biosciences announced the exercise of warrants for $4 million in gross proceeds in December 2024 and $9.6 million in gross proceeds in September 2025. The company announced financial results for the three and twelve months ended December 31, 2024, and for the three and nine months ended September 30, 2025. Revelation Biosciences received continued NASDAQ listing approval in February 2025. The company also announced dosing the first patient in the PRIME Phase 1b clinical study of Gemini in CKD patients in February 2025. In November 2025, the company successfully submitted and received acceptance of an end-of-phase 1 meeting package to the FDA, and in December 2025, engaged in discussions with the FDA regarding the clinical and approval pathway for Gemini for acute kidney injury. In January 2026, Revelation Biosciences announced the initiation of GMP manufacturing for its GEMINI drug and placebo to support later-stage clinical development. The company filed to sell 13.07 million shares of common stock by selling shareholders in September 2025 and filed for a secondary offering of about 5.1 million shares in September 2024.

Based on available data, there is insufficient information to establish a reliable seasonal profile for the demand of Revelation Biosciences, Inc.'s products and services. Only four years of data are available for REVB, which is considered inadequate for a robust seasonal analysis. While the broader Healthcare sector exhibits a period of seasonal strength from April 25 to December 4, this general sector trend cannot be directly attributed to the specific demand seasonality for Revelation Biosciences' individual products or services due to the limited company-specific data.

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immune system therapeutics and diagnostics within the Healthcare sector, specifically in Biotechnology and Pharmaceutical Products. The company is developing product candidates based on its Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD), a TLR4 agonist designed to stimulate the innate immune response. Major product candidates include GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease and GEM-SSI for surgical site infection. The company's pipeline also includes REVTx-99b for allergic rhinitis and chronic nasal congestion, REVDx-501, a rapid point-of-care diagnostic test for various respiratory viral infections, and REVTx-200, an intranasal immunomodulator adjunct.

Revelation Biosciences, Inc. was founded in 2020 and is headquartered in San Diego, California. Its primary operations are focused on research and development, with its geographic footprint largely centered around its base of operations.

Revelation Biosciences, Inc.'s brand reputation, particularly from an investment perspective over the past year, appears to be challenged. The company has received a consensus "Sell" rating from analysts, with an average rating score of 1.00 based on one sell rating and no buy or hold ratings. Its MarketRank™ score indicates that Revelation Biosciences scored higher than only 15% of companies evaluated by MarketBeat. The stock has trended down significantly, by 96.77% in the past year and 68.42% in the past six months, reflecting investor skepticism. The substantial decline in stock price and negative analyst sentiment suggest a challenging reputation within the investment community.

The ownership structure of Revelation Biosciences (REVB) stock is a mix of institutional, insider, and individual investors. Approximately 6.17% to 12.80% of the company's stock is owned by institutional investors, 14.24% to 14.50% by insiders, and a significant portion, around 79.33%, by public companies and individual investors. Major institutional owners and shareholders include Sabby Management, Llc, Armistice Capital, Llc, DRW Securities, LLC, Jane Street Group, Llc, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Bank Of America Corp /de/, UBS Group AG, Citigroup Inc and Danske Bank A/s. James Rolke is noted as owning the most shares of Revelation Biosciences. Insider sentiment for REVB has been positive, with high-impact open-market purchases from insiders.